{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018581","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.402213+00:00","generated_at":"2026-06-08T07:16:52.627653+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aprea reports Q3 net loss $3.2M; cash $25.4M; ATRN-1051 IND on track for Q4 2023","bullets":["Net loss of $3.2M ($0.86/sh) vs $4.0M ($2.32/sh) in Q3 2022; operating loss reduced to $3.5M.","Cash and equivalents $25.4M as of Sep 30, 2023; cash runway through Q4 2024.","ATRN-119 dose escalation at cohort 4 (350mg); dose expansion enrollment expected Q2 2024.","ATRN-1051 IND submission planned Q4 2023 with clearance Q1 2024; Phase 1/2a start H1 2024.","R&D expenses $2.1M (up from $1.1M) due to ATRN-1051 IND studies; G&A down to $1.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018581","json":"https://secwatch.observer/filing/0001558370-23-018581.json","markdown":"https://secwatch.observer/filing/0001558370-23-018581.md","text":"https://secwatch.observer/filing/0001558370-23-018581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/0001558370-23-018581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/apre-20231109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:16:52.627653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91223a113314ded3ba689726dd8419acd00546c2","claim":"Aprea Therapeutics, Inc. reported three and nine months ended September 30, 2023 results: net income a net loss of $3.2 million ($0.86 per basic share), EPS ($0.86 per basic share).","evidence_excerpt":"Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000155837023018581/0001558370-23-018581-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Net income","value":"a net loss of $3.2 million ($0.86 per basic share)"},{"label":"EPS","value":"($0.86 per basic share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}